Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia - Wikidata - thesis-toulmin - TriplyDB

Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia

Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia

http://www.wikidata.org/entity/Q34629553

about

Calsequestrin 2 and arrhythmias Catecholaminergic polymorphic ventricular tachycardia: An exciting new era Calcium dysregulation in atrial fibrillation: the role of CaMKII Channel Activity of Cardiac Ryanodine Receptors (RyR2) Determines Potency and Efficacy of Flecainide and R-Propafenone against Arrhythmogenic Calcium Waves in Ventricular Cardiomyocytes Inherited ion channel diseases: a brief review Current topics in catecholaminergic polymorphic ventricular tachycardia Flecainide: Current status and perspectives in arrhythmia management Channelopathies - emerging trends in the management of inherited arrhythmias Calsequestrin mutations and catecholaminergic polymorphic ventricular tachycardia TECRL, a new life-threatening inherited arrhythmia gene associated with overlapping clinical features of both LQTS and CPVT Exercise and Arrhythmias: A Double-Edged Sword.Targeting intracellular calcium cycling in catecholaminergic polymorphic ventricular tachycardia: a theoretical investigation.Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments.Follow-up with exercise test of effort-induced ventricular arrhythmias linked to ryanodine receptor type 2 gene mutations.The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands.Syncope and exercise-related ventricular tachycardia.Paradoxical effect of increased diastolic Ca(2+) release and decreased sinoatrial node activity in a mouse model of catecholaminergic polymorphic ventricular tachycardia.Left cardiac sympathetic denervation for the management of life-threatening ventricular tachyarrhythmias in young patients with catecholaminergic polymorphic ventricular tachycardia and long QT syndrome A family with recurrent sudden death and no clinical clue.Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.A novel cardiac ryanodine receptor gene (RyR2) mutation in an athlete with aborted sudden cardiac death: a case of adult-onset catecholaminergic polymorphic ventricular tachycardia.[Ion channel diseases in children].Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry.Genetic analysis of Iranian family with hereditary cardiac arrhythmias by next generation sequencing.The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia.RyR2R420Q catecholaminergic polymorphic ventricular tachycardia mutation induces bradycardia by disturbing the coupled clock pacemaker mechanism.Impact of genetics on the clinical management of channelopathies.Pharmacology and Toxicology of Nav1.5-Class 1 anti-arrhythmic drugs.KCNJ2 mutation causes an adrenergic-dependent rectification abnormality with calcium sensitivity and ventricular arrhythmia.Gender Differences in the Inheritance Mode of RYR2 Mutations in Catecholaminergic Polymorphic Ventricular Tachycardia Patients Patient-Specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia.Calcium cycling proteins and heart failure: mechanisms and therapeutics Efficacy of bilateral thoracoscopic sympathectomy in a patient with catecholaminergic polymorphic ventricular tachycardia.In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia.Accelerated sinus rhythm prevents catecholaminergic polymorphic ventricular tachycardia in mice and in patients.Gene mutations in cardiac arrhythmias: a review of recent evidence in ion channelopathies.Flecainide reduces Ca(2+) spark and wave frequency via inhibition of the sarcolemmal sodium current.Almanac 2011: Cardiac Arrhythmias and Pacing. The National Society Journals Present Selected Research that has Driven Recent Advances in Clinical Cardiology.Systems biology and cardiac arrhythmias A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses.

P2860

Q24300626-675DD71B-3869-4D06-9DCA-FF4D0E96F961 Q26747056-439B0DF0-7F45-4604-829C-206F50A884C6 Q27027326-3A564075-2AF0-4A28-BCCD-2A682C07AC9B Q27303698-D5F09CD5-9905-49B9-A87D-AED34D6206F0 Q28071914-3B262D71-529F-4E70-89CF-0EAB6B7FEC43 Q28076784-0BE012D1-E248-4AE8-BCE7-3ADD6205ED5F Q28081935-F9FF5C60-6B11-471D-8EA4-41C8456B0486 Q28085317-C6E58926-FFFA-448D-8D9B-41A8E5B2682D Q28262015-ED62334B-2DA5-4746-AF17-6FC022557DF1 Q29465809-48E253DC-F55C-48E8-AF1D-5A8D0BBABED5 Q30251499-30819B1B-C785-4F3D-A8C5-9571D581781E Q33160226-034F545D-D169-4516-A2A6-29FFE7C65AAC Q33160416-23E38A77-17DF-4F13-9F34-E7E3361CD4D7 Q33160839-C8041FF1-C076-466C-8101-7C45315DC2C0 Q33161041-361807FE-B52E-4B88-BF13-AAA701A1E5F7 Q33161248-F824490A-4BA7-474E-800C-C96DF3941D54 Q33161429-A0A12D40-F13F-4B32-8C06-A6E164DC4C35 Q33161560-824C7ABB-E994-4C1E-9BEA-C010A8DD848F Q33161934-A2B5A9B5-BFF2-4B20-B9FB-3291188EEFF9 Q33162208-15C48547-8CC9-4CA2-80EB-1ECF2F193AA9 Q33164590-332077F6-5E1C-4BB2-8109-2A9406940A8F Q33164649-01367CB8-260B-4ECD-811D-B5519D3E94D8 Q33165339-12346AFC-8DA1-4E57-B5CF-EF8736EEF36A Q33167089-F5B888CC-28F1-47F9-BC60-1418DA6C7F8A Q33167418-44E5F37D-1B82-4AE0-93A3-D5F436BDFCDE Q33168540-8184CE3B-75A4-4FB4-B0A2-33D66746BB6A Q34036797-F5CA62DE-50EB-4F95-B60D-2E8597ACCE6C Q34482842-CD4BE6F3-81A0-4D6A-99B3-CF56C13DACB6 Q34639203-E00531CB-FDD2-4E6D-9494-B407A44E62F5 Q35675536-29A2ABD9-1E0D-423F-91A0-D0A9DDD6A391 Q36169155-13CE1CC0-D6B9-46FB-B6F2-3C8E53D0DD73 Q36497155-8EB233FA-DEB2-4156-B382-B83D4F752133 Q36594593-FF6097FE-AB93-42E6-BECA-A2754610F515 Q36667578-BFB5B610-2DDF-4999-9833-FC1DCB338AC6 Q36696236-12A38883-3692-47F1-9E78-1B1F7D818520 Q36975788-34F9BAEE-D303-47E2-8FFC-FFE93AE51877 Q37023408-0C0F1132-CE42-42EE-9837-73655341F87E Q37066818-631F57CE-3BB3-436F-992A-8CBB51BBB9C9 Q37100421-64890DC2-A469-4E70-962E-98C8D54EF8E8 Q37305886-8D73BCB6-9BCD-4DE1-9B37-CB1D58CD0226

P2860

Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia

http://www.wikidata.org/entity/Q34629553

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Flecainide therapy reduces exe ...... orphic ventricular tachycardia

@ast

Flecainide therapy reduces exe ...... orphic ventricular tachycardia

@en

Flecainide therapy reduces exe ...... orphic ventricular tachycardia

@nl

type

label

Flecainide therapy reduces exe ...... orphic ventricular tachycardia

@ast

Flecainide therapy reduces exe ...... orphic ventricular tachycardia

@en

Flecainide therapy reduces exe ...... orphic ventricular tachycardia

@nl

prefLabel

Flecainide therapy reduces exe ...... orphic ventricular tachycardia

@ast

Flecainide therapy reduces exe ...... orphic ventricular tachycardia

@en

Flecainide therapy reduces exe ...... orphic ventricular tachycardia

@nl

P1433

Q34629553-50C3086C-5FD7-43B6-8A7C-791D6384D0E1

P1476

Q34629553-E13A5B8C-CF58-4071-A6FF-62377B892A31

P2093

Q34629553-009A8AFB-8AF8-4A0A-B032-96949D9939F3

Q34629553-21B8DF59-8F89-4C51-9ADB-7036E3C72B10

Q34629553-2255398C-B239-4C0E-8DDB-321742B37844

Q34629553-3E6AFC9E-2513-4754-9A74-94BAC5355A61

Q34629553-4AFD22CD-80E9-4CEE-B874-E462F3E53941

Q34629553-4F623C9D-E261-48D0-9399-982FD318B170

Q34629553-5B790297-706F-40B9-87F8-FF04BAB2D701

Q34629553-5BACD4AC-24E2-4266-B029-985F8CC58294

Q34629553-77BDEDF9-205C-4A66-BD42-2F820636223C

Q34629553-8A042325-174B-4A4A-99E0-3696E2F98C77

P2860

Q34629553-05131B8C-F79C-4854-9BA8-EA7523FD96DB

Q34629553-05AAEB2D-3E10-4A91-8154-2FE48B52908B

Q34629553-0C388866-7F97-4F03-93C5-3F08FC5515E0

Q34629553-0CB64FE9-07CA-45EB-A9DE-ED91BDDCE530

Q34629553-0EB69610-7D88-4483-BF28-778AB90E34E4

Q34629553-22D6FCA8-DAFB-4500-A944-5E9C97355B0F

Q34629553-36084DE8-EE19-4038-9FCE-CEC048C6F02A

Q34629553-36B974BA-AFF0-4D74-BDC1-7405BA1C5D32

Q34629553-37B26BF3-23D0-4BDE-9C4C-E023878B1568

Q34629553-39090B65-CD71-4E95-A5D2-E24AE03A3BB6

P304

Q34629553-E76A13F5-E07D-4967-980B-07D20C98B825

P31

Q34629553-F1B992D3-9BE0-46DA-8B63-1B47E9BA4C34

P356

Q34629553-9B038AB5-FD50-4A54-AA3F-9B3DDCD06985

P407

Q34629553-58E630E7-7C3D-46EB-877A-885195471505

P433

Q34629553-41D6DDB6-1A74-4753-84F7-5DAFE3EDD47E

P478

Q34629553-369492A3-FCF5-4560-828A-17C641B459EC

P50

Q34629553-B0C3B392-BCC0-4A76-BDC1-25A23C001DFD

Q34629553-D34E8CE9-2D8B-45B0-B942-05D316E9B3CF

P577

Q34629553-432439E6-12AF-4CF4-A73C-D3D88FB288B0

P5875

Q34629553-F9C23439-2D8C-415F-97E6-BAEEFAF99E15

P698

Q34629553-5D5F2431-10BB-43BD-89FB-D54FEC44D12F

P921

Q34629553-B565DB32-45B8-49D2-8642-44E9CA376A90

P932

Q34629553-B9E0AF05-C3D2-4584-8A38-1A46FA02CC72

P356

J.JACC.2011.01.026

P1433

Journal of the American College of Cardiology

P1476

Flecainide therapy reduces exe ...... orphic ventricular tachycardia

@en

P2093

Albert R Willems

http://www.w3.org/2001/XMLSchema#string

Andrew D Krahn

http://www.w3.org/2001/XMLSchema#string

Antoine Leenhardt

http://www.w3.org/2001/XMLSchema#string

Björn C Knollmann

http://www.w3.org/2001/XMLSchema#string

Christian van der Werf

http://www.w3.org/2001/XMLSchema#string

Frank A Fish

http://www.w3.org/2001/XMLSchema#string

Frederic Sacher

http://www.w3.org/2001/XMLSchema#string

Hiroshi Watanabe

http://www.w3.org/2001/XMLSchema#string

Julien Laborderie

http://www.w3.org/2001/XMLSchema#string

Maurits J van der Veen

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia

Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes

Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans

Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death

Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia

A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel

The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading fram

RyR2 mutations linked to ventricular tachycardia and sudden death reduce the threshold for store-overload-induced Ca2+ release (SOICR)

Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

P304

2244-2254

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACC.2011.01.026

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P50

Michel Haïssaguerre

Arthur A M Wilde

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51168835

http://www.w3.org/2001/XMLSchema#string

P698

21616285

http://www.w3.org/2001/XMLSchema#string

P921

catecholaminergic polymorphic ventricular tachycardia

P932

3495585

http://www.w3.org/2001/XMLSchema#string